Shopping Cart 0
Cart Subtotal
USD 0

Aprea AB-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase

Details

Aprea AB (Aprea) discovers and develops novel anticancer compounds targeting the tumor suppressor protein p53. The company's lead drug candidate includes APR-246, an anti-cancer compound that targets and reactivates the tumor suppressor protein p53, inducing programmed cell death in many human cancer cells. APR-246 also finds applications in the various solid and hematological (blood) tumors, including ovarian cancer, small cell lung cancer, esophageal cancer and AML (acute myeloid leukemia), among others. It carries out various research and development projects to develop compounds for different diseases. Aprea is headquartered in Solna, Stockholm, Sweden.

Aprea AB-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Aprea AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Aprea AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Aprea AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Aprea AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

Aprea AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Aprea AB, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

Aprea Raises USD50.7 Million in Series B Financing Round 10

Aprea Secures US$3.2 Million In Venture Financing 11

Acquisition 11

BrainsToVentures And Rosetta Capital Acquire Minority Stake In 13 Portfolio Companies Of Karolinska Development For US$34 Million 11

Aprea AB-Key Competitors 15

Key Employees 16

Locations And Subsidiaries 17

Head Office 17

Other Locations & Subsidiaries 17

Recent Developments 18

Corporate Communications 18

Jun 16, 2016: Aprea Names Christian S. Schade President and Chief Executive Officer 18

Product News 19

06/06/2016: Cancer drug trial success 19

Clinical Trials 20

Jun 06, 2016: Aprea AB Announces Efficacy and Safety Data in High-Grade Serous Ovarian Cancer Patients Treated with Investigational APR-246 Presented at 2016 ASCO Annual Meeting 20

Appendix 21

Methodology 21

About GlobalData 21

Contact Us 21

Disclaimer 21


List Of Figure

List of Figures

Aprea AB, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Aprea AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Aprea AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Aprea AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Aprea AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Aprea AB, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6

Aprea AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Aprea AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8


List Of Table

List of Tables

Aprea AB, Pharmaceuticals & Healthcare, Key Facts 1

Aprea AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Aprea AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Aprea AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Aprea AB, Deals By Therapy Area, 2011 to YTD 2017 8

Aprea AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Aprea Raises USD50.7 Million in Series B Financing Round 10

Aprea Secures US$3.2 Million In Venture Financing 11

BrainsToVentures And Rosetta Capital Acquire Minority Stake In 13 Portfolio Companies Of Karolinska Development For US$34 Million 11

Aprea AB, Key Competitors 15

Aprea AB, Key Employees 16

Aprea AB, Other Locations 17

Aprea AB, Subsidiaries 17

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Aprea AB (Aprea) discovers and develops novel anticancer compounds targeting the tumor suppressor protein p53. The company's lead drug candidate includes APR-246, an anti-cancer compound that targets and reactivates the tumor suppressor protein p53, inducing programmed cell death in many human cancer cells. APR-246 also finds applications in the various solid and hematological (blood) tumors, including ovarian cancer, small cell lung cancer, esophageal cancer and AML (acute myeloid leukemia), among others. It carries out various research and development projects to develop compounds for different diseases. Aprea is headquartered in Solna, Stockholm, Sweden.

Aprea AB-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Aprea AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Aprea AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Aprea AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Aprea AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

Aprea AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Aprea AB, Pharmaceuticals & Healthcare, Deal Details 10

Venture Financing 10

Aprea Raises USD50.7 Million in Series B Financing Round 10

Aprea Secures US$3.2 Million In Venture Financing 11

Acquisition 11

BrainsToVentures And Rosetta Capital Acquire Minority Stake In 13 Portfolio Companies Of Karolinska Development For US$34 Million 11

Aprea AB-Key Competitors 15

Key Employees 16

Locations And Subsidiaries 17

Head Office 17

Other Locations & Subsidiaries 17

Recent Developments 18

Corporate Communications 18

Jun 16, 2016: Aprea Names Christian S. Schade President and Chief Executive Officer 18

Product News 19

06/06/2016: Cancer drug trial success 19

Clinical Trials 20

Jun 06, 2016: Aprea AB Announces Efficacy and Safety Data in High-Grade Serous Ovarian Cancer Patients Treated with Investigational APR-246 Presented at 2016 ASCO Annual Meeting 20

Appendix 21

Methodology 21

About GlobalData 21

Contact Us 21

Disclaimer 21


List Of Figure

List of Figures

Aprea AB, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Aprea AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Aprea AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Aprea AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Aprea AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Aprea AB, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6

Aprea AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Aprea AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8


List Of Table

List of Tables

Aprea AB, Pharmaceuticals & Healthcare, Key Facts 1

Aprea AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

Aprea AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

Aprea AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

Aprea AB, Deals By Therapy Area, 2011 to YTD 2017 8

Aprea AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9

Aprea Raises USD50.7 Million in Series B Financing Round 10

Aprea Secures US$3.2 Million In Venture Financing 11

BrainsToVentures And Rosetta Capital Acquire Minority Stake In 13 Portfolio Companies Of Karolinska Development For US$34 Million 11

Aprea AB, Key Competitors 15

Aprea AB, Key Employees 16

Aprea AB, Other Locations 17

Aprea AB, Subsidiaries 17

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com
chat_bubbleLet's Chat